Pangea Pharmaceuticals Expands Access to Ergomar® Sublingual Tablets, Reinforcing Commitment to Patients and Providers.

• Ergomar® is the first and only FDA-approved sublingual treatment for migraines and cluster headaches in the U.S.
• Following Pangea’s acquisition in February 2024, efforts have accelerated to enhance nationwide patient access.
• Physician sampling program now available alongside $0 co-pay* assistance for eligible patients.

FORT LAUDERDALE, FL — June 10, 2025 — Pangea Pharmaceuticals is pleased to share continued momentum and expanded access for Ergomar® Sublingual Tablets (2 mg; Ergotamine Tartrate, USP; ANDA 087693), a unique migraine and cluster headache therapy that has gained significant traction since its reintroduction in early 2025. As the only FDA-approved sublingual option in its class, Ergomar® is redefining how providers treat—and patients experience—migraine relief.

Pangea assumed ownership of Ergomar® in February 2024, and since then, has remained laser-focused on advancing equitable access, provider education, and patient-centered support programs. With a legacy of clinical effectiveness and renewed emphasis on affordability and access, Ergomar® is once again empowering healthcare providers to help patients regain control from the often-disruptive impact of migraines and cluster headaches.

Advancing Access and Affordability
Since it’s reintroduction, Ergomar® has gained broad coverage through leading commercial insurers. To further minimize cost barriers:

• A $0 Co-Pay* Assistance Program* is available to eligible patients.
• A Physician Sampling Program allows HCPs to provide initial treatment and evaluate fit for patients without delay.

These programs underscore Pangea’s dedication to enabling timely, uninterrupted treatment—whether it’s a first-time diagnosis or a recurring episode of migraine or cluster headache.

“Our entire team at Pangea is relentlessly committed to empowering healthcare providers with clinically relevant, accessible treatments like Ergomar®,” said Anthony LaViola, CEO of Pangea Pharmaceuticals. “We’ve made it our mission to reintroduce Ergomar® in a way that reflects not just scientific value, but real-world patient needs. Through increased sampling, $0 co-pay* access for eligible patients, and a comprehensive HCP awareness campaign, we’re ensuring that more providers can recognize Ergomar®’s suitability for a broad range of patients—and that more patients can access it without unnecessary delays.”

“This is a milestone that reaffirms our focus on high-impact launches with meaningful patient benefit,” added Steve Flood, President of Pangea Pharmaceuticals.

One tablet. Sublingual speed. Zero delays.

More than 39 million Americans live with migraines and cluster headaches—often striking when you least expect them. Patients need relief that’s both rapid and reliable. Ergomar® fulfills this unmet need by offering fast symptom control while helping to minimize side effects and access barriers. Ergomar®’s 2 mg tablet dissolves under the tongue for fast-acting, caffeine- and aspartame-free relief, with no water needed and no risk of GI disruption.

Product Details & Prescribing Information
Ergomar® Sublingual Tablets (2 mg strength; NDC 81279-104-20) now available at participating pharmacies nationwide.

Important Safety Information

• Boxed Warning: Do not use Ergomar® with potent CYP 3A4 inhibitors (e.g., ritonavir, clarithromycin) due to the risk of serious, life-threatening peripheral ischemia.
• Contraindications: Hypersensitivity, pregnancy, coronary artery disease, peripheral vascular disease, uncontrolled hypertension, severe hepatic or renal impairment, sepsis, or coadministration with potent CYP 3A4 inhibitors.
• Warnings and Precautions: Risk of ergotism, vasospasm, and fibrotic complications with overuse or long-term use.
• Adverse Reactions: Nausea, vomiting, numbness, tingling, cold extremities, and other vasoconstrictive complications.

For full prescribing information, including detailed warnings and precautions, please visit www.ergomar.com. Report adverse events to Pangea Pharmaceuticals at 1-844-ERGOMAR (374-6627) or the FDA at www.fda.gov/medwatch.

*Certain restrictions and limitations apply.

About Pangea Pharmaceuticals
Founded in 2018, Pangea Pharmaceuticals is an emerging specialty pharmaceutical company dedicated to developing and delivering accessible, high-impact treatments across key therapeutic categories. With a growing portfolio and a patient-first approach, Pangea continues to lead with purpose—bridging gaps in care and transforming access into outcomes.

For more information, visit www.pangeapharm.com.

Media Contact
Rachel Osinoff
Phone: 914-438-1480
Email: info@pangeapharm.com
Website: www.pangeapharm.com

Follow Pangea Pharmaceuticals on social media:
LinkedIn | Instagram | Facebook @PangeaPharmaceuticals